Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive that combines a physical barrier with the controlled release of non-hormonal agents to prevent pregnancy. The device consists of a flexible silicone ring with a tightly woven polymer matrix across its center. This matrix contains ferrous gluconate (a form of iron), vitamin C, glycine, and polyglycolide microparticles. When inserted into the vagina at the end of menstruation and worn until the next period, Ovaprene acts by two complementary mechanisms: - Physically blocking sperm from entering the cervical canal via its knitted polymer barrier. - Releasing ferrous gluconate and other agents locally to create an environment that impairs sperm motility through lipid peroxidation reactions. Ovaprene is designed for continuous use throughout the menstrual cycle without requiring action at each intercourse or daily administration. It does not contain hormones and does not require clinician fitting. Clinical studies have shown it effectively immobilizes sperm and prevents their progression into cervical mucus[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ovaprene.